The new kid on the block: RET in lung cancer
- PMID: 23749525
- DOI: 10.1158/2159-8290.CD-13-0174
The new kid on the block: RET in lung cancer
Abstract
RET has recently been identified as a potential new oncogenic driver in a subset of patients with non-small cell lung cancer (NSCLC). In this issue of Cancer Discovery, Drilon and colleagues report preliminary trial data with a RET inhibitor in RET fusion-positive NSCLC, validating RET as a therapeutic target in lung cancer.
©2013 AACR.
Comment on
-
Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.Cancer Discov. 2013 Jun;3(6):630-5. doi: 10.1158/2159-8290.CD-13-0035. Epub 2013 Mar 26. Cancer Discov. 2013. PMID: 23533264 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical